AbbVie vs Merck & stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Merck & is more profitable, grows faster, is cheaper for its profits and has less debt.
Side by side
| AbbVie | Merck & | |
|---|---|---|
| $506 billion | $330 billion | |
| 6.9% | 28.1% | |
| +6.0% | +9.4% | |
| 119.7× | 18.1× | |
| 3.5 years | 1.2 years | |
| 12.0% | 17.8% | |
| 3.1% | 2.8% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: AbbVie vs Merck KGaA · AbbVie vs Moderna · AbbVie vs Novo Nordisk · AbbVie vs Novartis · Merck & vs Amgen · Merck & vs argenx · Merck & vs Bayer · Merck & vs Gilead Sciences

